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1410(e.g., Percusurge GuardWire, Min-
neapolis, Minnesota). In an earlier
meta-analysis, we had demonstrated
a salutary effect of aspiration
thrombectomy devices on my-
ocardial reperfusion parameters
and mortality, whereas mechan-
ical thrombectomy devices ap-
peared to be associated with an
increased risk of mortality (1).See page 1419These ﬁndings were incorporated
into the 2009 American College
of Cardiology (ACC)/Ameri-
can Heart Association (AHA)
guidelines for the management of
patients with STEMI, and aspi-ration thrombectomy currently carries a Class IIa recom-
mendation for use with primary PCI (2). However, the most
recent trial on this topic showed no beneﬁt on ﬁnal infarct
size at 30 days with routine aspiration thrombectomy in
high-risk STEMI patients undergoing primary PCI (3).
Similarly, the JETSTENT (AngioJet Rheolytic Throm-
bectomy Before Direct Infarct Artery Stenting With Direct
Stenting Alone in Patients With Acute Myocardial Infarc-
tion) trial (4) demonstrated a beneﬁcial effect on major
adverse cardiac events (MACE) with adjunctive mechanical
thrombectomy over routine PCI in these patients. Because
additional studies and prolonged follow-up of earlier trials
have now been reported, we sought to perform an updated
meta-analysis to determine the relative magnitude of beneﬁt
of adjunctive aspiration and mechanical thrombectomy
devices on clinical and surrogate markers of reperfusion as
compared with conventional primary PCI alone in patients
presenting with STEMI.
Methods
Literature review. A computerized literature search of the
Cochrane, Embase, and MEDLINE databases was con-
ducted for randomized controlled trials published from
January 1996 to December 2012, using the Medical Subject
Heading and the key word search terms thrombectomy,
thrombus aspiration, thromboaspiration, aspiration, mechanical,
infarction, and myocardial infarction. Only English-language
studies were included. We also obtained recently presented
data at national and international cardiology conferences.
We also corresponded with authors when ﬁnal results were
not available and reviewed other meta-analyses on this topic.
Additionally, we used Internet-based sources of information
(http://www.cardiosource.com, http://www.clinicaltrials.gov,
http://www.theheart.org, and http://www.tctmd.com).
Selection criteria. We selected studies that randomized
patients within 12 h of acute myocardial infarction (AMI) toeither: 1) aspiration thrombectomy and primary PCI versus
primary PCI alone or 2) mechanical thrombectomy and
primary PCI versus primary PCI alone. We only included
studies that reported clinical outcomes data and/or markers
of myocardial reperfusion. We excluded studies that per-
formed thrombectomy on saphenous vein grafts or that
compared one thrombectomy device to another.
Outcomes/data abstraction. The primary clinical endpoint
of interest was all-cause mortality. Secondary endpoints were
recurrence of MI, target vessel revascularization, and
MACE (composite of death, MI, and target vessel revas-
cularization). Myocardial reperfusion was examined at 2
distinct time frames: immediately post-procedure (myocar-
dial blush grade and ST-segment resolution) and at 1 to 3
months (change in infarct size and left ventricular ejection
fraction after primary PCI). Deﬁnitions used to abstract
outcomes are outlined in the Online Appendix. Outcomes
were tabulated by 2 independent reviewers (D.J.K., A.A.B.)
and the number of events that occurred among each arm of
a trial recorded. Discrepancies were resolved through
discussion, and a third reviewer (D.L.B.) when necessary.
Statistical analysis. The PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) statement
was followed for this meta-analysis (5). For all clinical
outcomes, an intention-to-treat analysis was utilized. For the
reperfusion and infarct size outcomes, treatment-received (or
per-protocol) analysis was utilized because there were gener-
ally fewer patients available for the determination of these
outcomes. Summary relative risks (RRs) and their corre-
sponding 95% conﬁdence intervals (CIs) were computed
for each dichotomous outcome using ﬁxed- and random-
effects (DerSimonian and Laird method) models (6). For
outcomes with signiﬁcant heterogeneity, the random-effects
model is reported in the text and ﬁgures; for all others, the
ﬁxed-effects models are reported. If a study had no events in
1 group, we added 0.5 to each cell of the 2  2 table for that
study to compute the summary RR. Heterogeneity between
studies was assessed by calculating an I2 statistic and publi-
cation bias with Begg’s funnel plot method (7). For infarct
size, the weighted mean difference (WMD) and corre-
sponding 95% CIs were computed using random-effects
modeling (8). Where these data were unavailable (4,9), they
were imputed from available data using published approaches
(10,11). Where signiﬁcant heterogeneity was noted, the
impact of important baseline covariates was examined using
random-effects meta-regression, including baseline Throm-
bolysis In Myocardial Infarction (TIMI) ﬂow grade 0/1,
glycoprotein IIb/IIIa inhibitor use, direct stenting, and total
ischemic time. As a form of sensitivity analysis, we repeated
the aspiration thrombectomy versus conventional primary
PCI analyses after exclusion of the TAPAS (Thrombus
Aspiration during Percutaneous Coronary Intervention in
Acute Myocardial Infarction Study) (12). A sensitivity anal-
ysis was also planned after removing studies of low meth-
odologic quality based on bias assessment (13). Because the
experimental arm was an interventional device, concealment
Table 1 Baseline Characteristics of the Patient Population
First Author/Study (Year) (Ref. #) Device
Thrombectomy/Conventional Primary PCI
Clopidogrel
Loadingy
Direct Stenting in
Thrombectomy Arm, %
Follow-Up Duration,
Monthsn
Age,
Mean, Yrs
Baseline
TIMI Flow Grade 0/1, %
Mean Ischemic
Time, h*
GP IIb/IIIa
Inhibitor, %
Aspiration thrombectomy vs. conventional primary PCI trials
Dudek et al. (2004) (18) Rescue 40/32 57/59 79/66 4.3/3.9 0/0 Yes NA H
REMEDIA (2005) (16) Diver CE 50/49 61/60 86/90 4.6/5.0* 68/63 Yes 66 1
DEAR-MI (2006) (14) Pronto 74/74 57/60 81/73 3.4/3.3 100/100 No 70 1
De Luca et al. (2006) (15) Diver CE 38/38 67/65 100/100 7.2/7.6 100/100 No 92 6
Kaltoft et al. (2006) (9) Rescue 108/107 65/63 68/69 4.0/3.5 96/93 Yes 81 1
TAPAS (2008) (12) Export 535/536 63/63 55/60 3.2/3.1 93/90 Yes 55 12
Chao et al. (2008) (22) Export 37/37 60/62 NA 5.6/5.9 19/32 Yes 51 6
EXPORT (2008) (21) Export 120/129 59/61 99/100 6.0/5.1 4/14 NA 44 1
VAMPIRE (2008) (19) TVAC 180/175 63/64 75/75 6.3/7.1 0/0 No NA 8
EXPIRA (2009) (20) Export 88/87 67/65 NA 6.2/6.1 100/100 Yes 76 9
Lipiecki et al. (2009) (24) Export 20/24 59/59 100/96 7.1/7.4 30/74 Yes 50 H
Liistro et al. (2009) (25) Export 55/56 64/65 69/76 3.2/3.5 100/100 Yes 21 6
PIHRATE (2010) (17) Diver CE 100/96 61/59 97/98 NA 8/11 Yes 75 6
Ciszewski et al. (2011) (23) Rescue/Diver CE 67/70 64/64 90/91 5.6/5.6 84/80 Yes 79 H
INFUSE-AMI (2012) (3) Export 229/223 61/59 73/70 2.4/2.7 50/50 Yes NA 1
MUSTELA (2012) (33) Export 50/104 62/63z 95/81z 3.8/3/5z 100/100 Yes NA 12
Noel et al. (abstr. 2005) (26) Export 24/26 61 NA 4.7 NA NA 83 H
NONSTOP (abstr. 2004) (27) Rescue 129/129 64/66 NA NA NA NA NA H
Mechanical thrombectomy vs. conventional primary PCI trials
Beran et al. (2002) (32) X-sizer 30/31 56/54 80/74 4.9/4.7 73/68 No 42 1
Napodano et al. (2003) (31) X-sizer 46/46 61/64 74/85 4.0/3.4 43/41 No 61 1
Florence (2004) (30) AngioJet 50/50 63/66 76/80 3.9/4.4 98/98 No 94 1
X AMINE ST (2005) (29) X-sizer 100/101 61/62 NA 4.2/4.4 55/65 No 60 6
AIMI (2006) (28) AngioJet 240/240 60/60 68/63 5.1/5.0 95/94 Yes NA 6
JETSTENT (2010) (4) AngioJet 256/245 63/64 84/84 2.7/2.8 97/98 Yes 94 12
MUSTELA (2012) (33) AngioJet 54/104 62/63z 95/81z 3.8/3.5z 100/100 Yes NA 12
*Deﬁned as onset of ischemic symptoms until PCI, except where noted which is onset of symptoms until angiography. yEither pre- or post-procedure. zValues for all thrombectomy (aspiration þ mechanical) vs. conventional primary PCI alone.
AIMI ¼ AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction; DEAR-MI ¼ Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction; EXPIRA ¼ Thrombectomy With Export Catheter in Infarct-Related Artery
During Primary Percutaneous Coronary Intervention; GP ¼ glycoprotein; H ¼ follow-up to hospital discharge; INFUSE-AMI ¼ Infuse–Acute Myocardial Infarction; JETSTENT ¼ AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting With Direct Stenting Alone in
Patients With Acute Myocardial Infarction; MUSTELA ¼ MUltidevice Thrombectomy in Acute ST-Segment ELevation Acute Myocardial Infarction; NA ¼ not available; NONSTOP ¼ Intracoronary Aspiration before coronary Stenting in Patients with Acute Myocardial Infarction;
PIHRATE ¼ Polish-Italian-Hungarian RAndomized ThrombEctomy Trial; PRISMA ¼ Preferred Reporting Items for Systematic reviews and Meta-Analyses; REMEDIA ¼ Randomized Evaluation of the Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in
Primary and Rescue Angioplasty; TAPAS ¼ Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study; TIMI ¼ Thrombolysis In Myocardial Infarction; VAMPIRE ¼ VAcuuM asPIration Thrombus REmoval; X AMINE ST ¼ X-Sizer in AMI for
Negligible Embolization and Optimal ST Resolution.
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1412of allocation sequence was not possible. With the exception of
a few studies (mostly abstracts) where it was unclear, outcome
assessment was blinded in all trials. Thus, a sensitivity analysis
based on quality was not pursued.
Mean follow-up was weighted according to the sample sizes
of individual trials. All p values were 2-tailed, with statistical
signiﬁcance set at 0.05, and CIs were calculated at the 95% level.
All analyses were performed using STATA software version
10.0 (STATA Corporation, College Station, Texas).
Results
A total of 25 trials in 5,534 patients met our selection
criteria (3,4,9,12,14–33). Of these, 1,944 patients under-
went adjunctive aspiration thrombectomy; 779, adjunctive
mechanical thrombectomy; and 2,811, conventional primary
PCI alone. The baseline characteristics of the included patients
are listed in Table 1. The mean ischemic time ranged from 2.4
to 7.6 h. TIMI ﬂow grade 0/1 at baseline was noted in 63% to
100% of patients. All patients received aspirin beforeTable 2 Imaging Follow-Up
First Author/Study
(Year) (Ref. #) n
% of Clinical
Follow-Up
Final Infarct Size, %
Thrombectomy
Conventiona
Primary PCI
Aspiration thrombectomy vs. conventional primary PCI
Dudek et al.
(2004) (18)
72 100 NA NA
Kaltoft et al.
(2006) (9)
189 88 15.0  15.6 7.5  11.9
Chao et al.
(2008) (22)
74 100 NA NA
VAMPIRE
(2008) (19)
216 61 NA NA
EXPIRA
(2009) (20)
72 41 9.0  4.5 11.0  8.7
Lipiecki et al.
(2009) (24)
40 100 30.6  15.8 28.5  17.9
Liistro et al.
(2009) (25)
111 100 NA NA
Ciszewski et al.
(2011) (23)
129 94 23.1  13.3 28.9  10.2
INFUSE-AMI
(2012) (3)
353 78 15.9  9.7 16.7  10.6
MUSTELA
(2012) (33)
113 73 21.3  11.3 19.3  10.6
Noel et al. (abstr.
2005) (26)
50 100 12.9  9.6 20.9  7.8
Mechanical thrombectomy vs. conventional primary PCI
Napodano et al.
(2003) (31)
92 100 NA NA
Florence
(2004) (30)
100 100 13.0  11.6 21.2  18.0
AIMI (2006) (27) 402 84 12.5  12.1 9.8  10.9
JETSTENT
(2010) (4)
425 85 11.8  15.2 12.7  13.7
MUSTELA
(2012) (33)
116 75 17.5  9.6 19.3  10.6
*Final infarct size measured with SPECT, ﬁnal ejection fraction measured by CMR. y21 days.
CMR ¼ cardiac magnetic resonance imaging; H ¼ hospital; SPECT ¼ single-photon emission computethe procedure. Although the majority of patients received
a thienopyridine pre- or post-procedure, this information was
unavailable in 3 trials (26,27,33). Glycoprotein IIb/IIIa
inhibitor use was variable. It was disallowed in the VAMPIRE
(Vacuum Aspiration Thrombus Removal) trial (19) and in the
trial by Dudek et al. (18); it was part of a 2 2 factorial design
in the INFUSE-AMI (Infuse–Acute Myocardial Infarction)
trial (50%) (3), and it was administered to all patients in 4 trials,
either upstream (14,15,20) or intraprocedurally (25). Use of
direct stenting ranged from 21% to 94%.
Aspiration thrombectomy versus conventional primary
PCI (18 trials, n [ 3,936). IMMEDIATE MYOCARDIAL
REPERFUSION. The incidence of TIMI blush grade 3 post-
procedure was 63.6% in the aspiration thrombectomy arm
versus 48.5% with PCI alone (RR: 1.37, 95% CI: 1.19 to 1.59;
p< 0.0001). There was evidence of high heterogeneity among
the studies (I2: 87.8%). Similarly, the incidence of com-
plete ST-segment resolution was higher in the aspiration
thrombectomy arm (55.8% vs. 44.3%; RR: 1.31; 95% CI: 1.16
to 1.48; p< 0.0001). There was evidence of high heterogeneityFinal Ejection Fraction, %
Follow-Up,
Months
Method of
Assessment
l
Thrombectomy
Conventional
Primary PCI
60.3  9.2 55.3  14.7 3 Echo
51.0  10.4 53  8.2 1 SPECT
56.0  10.0 57.0  10.0 1 Echo
57.1  12.5 56.7  12.3 6 Ventriculogram
49.0  9.3 46.7  10.6 3 CMR
48.0  12.0 45.0  11.0 H SPECT/CMR*
55.0  6.0 49.0  8.0 6 Echo
NA NA H SPECT
49.6  10.0 49.5  11.7 1 CMR
57.0  10.0 59.0  11.0 3 CMR
NA NA H CMR
51.9  7.7 49.9  8.9 1 Echo
NA NA 1 SPECT
51.3  11.5 52.3  10.9 1y SPECT
NA NA 1 SPECT
NA NA 3 CMR
d tomography; other abbreviations as in Table 1.
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1413among the studies (I2: 60.9%) (Online Fig. 1).Meta-regression
did not identify a difference based on baselineTIMI ﬂow grade
0/1, glycoprotein IIb/IIIa inhibitor use, direct stenting, or total
ischemic time for either of these outcomes.
FINAL INFARCT SIZE AND EJECTION FRACTION. Information
on ﬁnal infarct size was available in 7 studies (n ¼ 950), and
it was studied using delayed enhancement - cardiac magnetic
resonance imaging (DE-CMR) in 4 studies (3,20,26,33)
and using technetium-99m sestamibi in the other 3
(9,23,24) (Table 2). The mean duration of follow-up was
35.9 days (range: hospital discharge to 6 months). There was
no difference in ﬁnal infarct size between the aspiration
thrombectomy and PCI-only arms (17.1% vs. 17.3%;
WMD: –0.85%; 95% CI: –4.37% to 2.67%; p ¼ 0.64). On
restricting the analysis to DE-CMR studies only, there was
still no difference in ﬁnal infarct size between the 2 arms
(WMD: –1.92%, 95% CI: –5.04% to 1.20%; p ¼ 0.23).
Information on ﬁnal ejection fraction was available in 9
studies and was obtained using CMR in 4 studies
(3,20,24,33), SPECT in 1 (9), echocardiography in 3
(18,22,25), and cine-ventriculography in 1 (19) (Table 2).
There was no difference in ﬁnal ejection fraction between
the 2 arms (53.0% vs. 52.8%; WMD: 1.09%; 95% CI:
–1.06% to 3.24%; p ¼ 0.32) (Online Fig. 2). Further, no
difference was noted on restricting the analysis to studies
assessing ejection fraction beyond 1 month (n ¼ 6) (WMD:
2.32%; 95% CI: –0.89% to 5.53%; p ¼ 0.16).
CLINICAL OUTCOMES. The weighted mean duration of
follow-up was 5.9 months (range: hospital discharge to
12 months). The primary endpoint of all-cause mortality was
signiﬁcantly lower in the aspiration thrombectomy arm as
compared with the PCI-only arm (2.7% vs. 3.9%; RR: 0.71;
95% CI: 0.51 to 0.99; p ¼ 0.049). There was no evidence of
heterogeneity (I2: 0%) or publication bias (p ¼ 0.60). A
random-effects model yielded similar results (RR: 0.73; 95%
CI: 0.52 to 1.03; p ¼ 0.07). On analyzing by duration of
follow-up, there was no signiﬁcant mortality beneﬁt within
1 month (RR: 0.69; 95% CI: 0.43 to 1.08; p ¼ 0.11),
but mortality was signiﬁcantly lower with aspiration throm-
bectomy at 6 to 12 months of follow-up (RR: 0.67; 95% CI:
0.45 to 1.00; p ¼ 0.05). Reinfarction (1.6% vs. 2.4%; RR:
0.68; 95% CI: 0.42 to 1.10; p ¼ 0.11) and target vessel
revascularization (6.9% vs. 8.7%; RR: 0.79; 95% CI: 0.61 to
1.02; p ¼ 0.06) were similar between the 2 arms, but
numerically lower in the aspiration thrombectomy arm. The
composite MACE outcome was signiﬁcantly lower in the
aspiration thrombectomy arm over the duration of follow-up
(10.8% vs. 14.0%; RR: 0.76; 95% CI: 0.63 to 0.92;
p¼ 0.006). All strokes were similar between the 2 arms (0.7%
vs. 0.4%; RR: 1.31; 95% CI: 0.30 to 5.79; p ¼ 0.72) (Fig. 1).
SENSITIVITY ANALYSIS. On excluding TAPAS, TIMI blush
grade 3 (RR: 1.37; 95% CI: 1.18 to 1.59; p < 0.0001) and
ST-segment resolution (RR: 1.33; 95% CI: 1.15 to 1.54;
p < 0.0001) were still signiﬁcantly improved with aspirationthrombectomy over conventional primary PCI alone. MACE
events remained signiﬁcantly lower with aspiration throm-
bectomy (RR: 0.69; 95% CI: 0.51 to 0.93; p ¼ 0.016), driven
predominantly by a reduction in target vessel revascularization
(RR: 0.66; 95% CI: 0.43 to 1.01; p ¼ 0.06).There were no
differences in mortality (RR: 0.83; 95% CI: 0.51 to 1.32;
p ¼ 0.42) or reinfarction (RR: 0.90; 95% CI: 0.45 to 1.81;
p ¼ 0.76) between the two arms.
Mechanical thrombectomy versus conventional primary
PCI (7 trials, n [ 1,598). IMMEDIATE MYOCARDIAL
REPERFUSION. The incidences of TIMI blush grade 3 post-
procedure were 48.8% in the mechanical thrombectomy arm
versus 49.5% with PCI alone (RR: 1.09; 95% CI: 0.86 to
1.38; p ¼ 0.48). There was evidence of high heterogeneity
among the studies (I2: 75.0%). However, the incidence
of complete ST-segment resolution was higher in the
mechanical thrombectomy arm (74.9% vs. 63.7%; RR: 1.25;
95% CI: 1.06 to 1.47; p ¼ 0.007). There was evidence of
high heterogeneity among the studies (I2: 76.7%) (Online
Fig. 3). Meta-regression did not identify a difference in
outcomes based on baseline TIMI ﬂow grade 0/1, glyco-
protein IIb/IIIa inhibitor use, direct stenting, or total
ischemic time for either of the 2 outcomes.
FINAL INFARCT SIZE AND EJECTION FRACTION. Data on ﬁnal
infarct size were available for 4 studies (n ¼ 1,043), and
studied usingDE-CMR in 1 study (33) andwith technetium-
99m sestamibi in the other 3 (4,28,30) (Table 2). The mean
duration of follow-up was 33.2 days (range: 21 to 90 days).
There was no difference in ﬁnal infarct size between the
mechanical thrombectomy and PCI-only arms (12.7% vs.
13.3%; WMD: –1.34%; 95% CI: –4.98 to 2.29; p ¼ 0.47)
(Online Fig. 4). Final ejection fraction could not be analyzed
because data were available from 2 studies only.
CLINICAL OUTCOMES. The weighted mean duration of
follow-up was 6.2 months (range: 1 to 12 months). The
primary endpoint of all-cause mortality was similar between
the mechanical thrombectomy and PCI-only arms (4.5% vs.
3.9%; RR: 1.20; 95% CI: 0.64 to 2.23; p ¼ 0.57). There was
evidence of moderate heterogeneity (I2: 30%), but no
evidence of publication bias (p ¼ 1.0). Meta-regression did
not identify any difference in mortality based on baseline
TIMI ﬂow grade 0/1, glycoprotein IIb/IIIa inhibitor use,
direct stenting, or total ischemic time. Reinfarction (0.8% vs.
1.4%; RR: 0.62; 95% CI: 0.23 to 1.62; p ¼ 0.32), target
vessel revascularization (4.0% vs. 5.1%; RR: 0.74; 95% CI:
0.48 to 1.16; p ¼ 0.19), all strokes (1.3% vs. 0.4%; RR: 2.74;
95% CI: 0.93 to 8.01; p ¼ 0.07), and the composite MACE
outcome (10.1% vs. 10.9%; RR: 1.10; 95% CI: 0.59 to 2.05;
p ¼ 0.77) were all similar between the mechanical throm-
bectomy and PCI-only arms (Fig. 2).
Discussion
Our meta-analysis of data from 5,534 patients with AMI in
25 trials indicates that as compared with conventional
Figure 1 Summary Plot for Clinical Outcomes for Aspiration Thrombectomy Versus Conventional Primary PCI
PCI ¼ percutaneous coronary intervention; RR ¼ risk ratio.
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1414primary PCI alone, aspiration thrombectomy was associated
with a signiﬁcant 24% reduction in MACE, including a 29%
reduction in all-cause mortality at 6 months’ median follow-
up. Rates of reinfarction and target vessel revascularization
were also numerically lower. On the other hand, mechanical
thrombectomy had a neutral effect on clinical outcomes as
compared with conventional primary PCI alone, with
a consistent and concerning trend toward a higher incidence
of stroke in all trials evaluated.
Given the importance of this topic and disparate results
from the different clinical trials, a number of prior meta-
analyses have been conducted (34–36). However, they have
been limited by their duration of follow-up (30 days) and by
combining all available devices into one thrombectomy cate-
gory. Our ﬁndings extend ﬁndings from these prior meta-
analyses, in that although no beneﬁt in clinical outcomes
was noted with aspiration thrombectomy at 30 days, we report
a beneﬁt at 6 to 12 months of follow-up. Our immediate
reperfusion results are also similar to the only published head-to-head trial (n ¼ 99) between the 2 types of devices wherein
aspiration thrombectomy resulted in superior reperfusion as
compared with mechanical thrombectomy (37).
In the context of aspiration thrombectomy, 2 trials
deserve special mention. On one hand, the results of the
recent INFUSE-AMI trial may have caused uncertainty in
the minds of some cardiologists regarding the utility of
adjunctive thrombectomy for primary PCI patients. The
primary endpoint for the INFUSE-AMI trial was ﬁnal
infarct size on DE-CMR, and was similar at 30 days
between the aspiration thrombectomy and conventional
primary PCI arms alone. Our ﬁndings are reassuring in that
despite the inclusion of INFUSE-AMI, there remains
a continued mortality beneﬁt with aspiration thrombectomy
at 6 to 12 months over conventional primary PCI. On the
other hand, the only trial to show a mortality beneﬁt with
aspiration thrombectomy was TAPAS. This trial has been
criticized for numerous reasons. These include possible
selection bias (single-center study), unclear mechanism (no
Figure 1 Continued
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1415difference in enzymatic infarct size post-procedure but
a signiﬁcant difference in cardiovascular and all-cause
mortality at 1 year), and the possibility of chance (the trial
was not originally powered for mortality) (12). Our sensi-
tivity analysis, however, suggests that even after exclusion of
TAPAS from the analysis, there was still a signiﬁcant
reduction in MACEs at 6 months, driven predominantly by
a reduction in target vessel revascularization rates. This could
be due to better sizing of stents during the index procedure
or less stent thrombosis as a result of thrombus removal (38).
Along these lines, it is interesting that numerically lower
target vessel revascularization rates at 6 to 12 months were
noted with both aspiration and mechanical thrombectomy
compared with conventional primary PCI. Could thrombus
extraction and less target vessel revascularization/late stent
thrombosis thus represent an alternative mechanism for
long-term clinical beneﬁt with aspiration thrombectomy
despite no difference in infarct size at 1 month compared
with conventional primary PCI? This ﬁnding is hypothesis
generating and needs further study. In a recent study, the
reference vessel diameter and minimal lumen diameteron dedicated quantitative angiographic analysis were both
signiﬁcantly greater with aspiration thrombectomy as com-
pared with conventional primary PCI. Moreover, the mean
stent area on optical frequency domain imaging was
numerically larger with aspiration thrombectomy (39). An
interesting ﬁnding in our analysis is the discrepancy between
infarct size and left ventricular ejection fraction at 1 month
and clinical outcomes at 6 to 12 months. What might
explain this disconnect? As far as infarct size is concerned, it is
widely appreciated that SPECT imaging has lower spatial
resolution than does DE-CMR, especially for subendocardial
infarcts (40). Thus, although SPECT studies were included to
increase overall power, the addition of SPECT studies toDE-
CMR studies to compare ﬁnal infarct size estimates may have
diluted the results. However, even after exclusion of the
SPECT studies, we still noted that there was no difference in
infarct size with aspiration thrombectomy. In the case of left
ventricular ejection fraction, although there is good overall
correlation between SPECT and CMR, discrepancies may be
large for small changes (41). Two-dimensional echocardiog-
raphy and cine-ventriculography do not have the same
Figure 2 Summary Plot for Clinical Outcomes for Mechanical Thrombectomy Versus Conventional Primary PCI
PCI ¼ percutaneous coronary intervention; WMD ¼ weighted mean difference.
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Also, as outlined in Table 2, a signiﬁcant proportion of
patients clinically followed up in these trials did not have
evaluableCMR studies (e.g., 22% in INFUSE-AMI and 59%
in EXPIRA). This might have created selection bias and also
a reduction in power to detect a true difference. From a tech-
nical standpoint, none of the DE-CMR studies reported
image intensity thresholds utilized for infarct size quantiﬁ-
cation (44). Signiﬁcant interstudy variability may have resul-
ted if different deﬁnitions were used by different trials (45).
Finally, surrogate endpoints do not always translate into
clinically relevant outcomes, as has been noted several times
before (46).
Our ﬁndings argue against a routine role for mechanical
thrombectomy in patients undergoing primary PCI. A
higher risk of stroke with mechanical thrombectomy, as we
previously reported (1), and further conﬁrmed in this study is
also concerning. However, it should be noted that the
combined sample size of the mechanical thrombectomy trials
was <50% that of the aspiration thrombectomy trials. It is
possible that the inclusion of larger mechanical thrombec-
tomy trials in the future may show a different result.
Study limitations. Because this was a meta-analysis, the
validity of our results is dependent on the validity of the
studies included. We did not include patient-level data. We
also included data that have been reported only in conference
presentations or in abstract form and so have not undergone
peer review. This inclusion was necessary to maximize the
utilization of all available data on this important topic. Theresults of our sensitivity analysis suggest that results obtained
by including data from abstracts did not differ signiﬁcantly
from results obtained from published manuscripts only (data
not shown). We did not include other measures of infarct
size, such as creatine kinase-myocardial band or troponin
measurements, due to inconsistent reporting.
Two large multicenter trials comparing aspiration throm-
bectomy to conventional primary PCI, both powered for
clinical endpoints, are currently ongoing (47,48). Until such
time that these results are available, our current analysis
supports the routine use of aspiration thrombectomy devices
as adjunctive therapy in STEMI patients undergoing primary
PCI over conventional primary PCI alone. The current IIa
recommendation in the ACC/AHA STEMI guidelines also
appears justiﬁed. Mechanical thrombectomy, on the other
hand, does not appear to affect clinical outcomes and cannot
be recommended for routine use in this patient population at
this time.
Conclusions
Thrombectomy during AMI by manual catheter aspiration,
but not mechanically, is beneﬁcial in reducing MACE,
including mortality, at 6 to 12 months compared with
conventional PCI alone.
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APPENDIX
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online version of this article.
